1 |
Fasnacht MS, Tolsa JF, Beghetti M; Swiss Society for Pulmonary Arterial Hypertension. The Swiss registry for pulmonary arterial hypertension: the paediatric experience. Swiss Med Wkly 2007;137:510-3.
|
2 |
Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009;95:312-7.
|
3 |
Fraisse A, Jais X, Schleich JM, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 2010;103:66-74.
DOI
ScienceOn
|
4 |
van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011;124:1755-64.
DOI
ScienceOn
|
5 |
Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012;379:537-46.
DOI
ScienceOn
|
6 |
Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012;125:113-22.
DOI
|
7 |
Zhou AQ, Zhang QY, DU JB. [Research on pulmonary hypertension in children: present and future]. Zhonghua Er Ke Za Zhi 2011;49:881-5.
|
8 |
Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S55-66.
DOI
|
9 |
Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 2011;37:665-77.
DOI
ScienceOn
|
10 |
Ivy D. Advances in pediatric pulmonary arterial hypertension. Curr Opin Cardiol 2012;27:70-81.
DOI
ScienceOn
|
11 |
Ivy DD, Rosenzweig EB, Lemarié JC, Brand M, Rosenberg D, Barst RJ. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 2010;106:1332-8.
DOI
ScienceOn
|
12 |
Fu LJ, Zhou AQ, Guo Y, Zhao PJ, Huang MR, Li F. [Adenosine for pulmonary vasodilator testing in children with idiopathic pulmonary arterial hypertension]. Zhonghua Er Ke Za Zhi 2011;49:886-9.
|
13 |
Zhang QY, Du JB. Progress on treatment or pulmonary hypertension in children. J Clin Pediatr 2010;28:607-10.
|
14 |
Tissot C, Ivy DD, Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension. J Pediatr 2010;157:528-32.
DOI
ScienceOn
|
15 |
Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004;110:660-5.
DOI
ScienceOn
|
16 |
Simonneau G, Barst RJ, Gaile N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
DOI
ScienceOn
|
17 |
Rosenzweig EB, Krishnan U, Takatsuki S, Kerstein J, Calderbank M, Ivy DD. Inhaled treprostinil in pediatric pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;183:A6143.
|
18 |
Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:161-9.
DOI
ScienceOn
|
19 |
Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin- receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358: 1119-23.
DOI
ScienceOn
|
20 |
Simpson CM, Penny DJ, Cochrane AD, et al. Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension. J Heart Lung Transplant 2006;25:469-73.
DOI
ScienceOn
|
21 |
Hislop AA, Moledina S, Foster H, Schulze-Neick I, Haworth SG. Longterm efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J 2011;38:70-7.
DOI
ScienceOn
|
22 |
Xu ZM, Zhu LM, Cai XM, Ji G, Liu JF, Su ZK. [Outcome of oral bosentan in children with congenital heart disease associated pulmonary arterial hypertension]. Zhonghua Yi Xue Za Zhi 2009;89:2106-9.
|
23 |
van Loon RL, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 2007;154:776-82.
DOI
ScienceOn
|
24 |
Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 2008;64:200-4.
DOI
ScienceOn
|
25 |
Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154:379-84, 384.e1-2.
|
26 |
Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebocontrolled, dose-ranging study of oral sildenafil citrate in treatmentnaive children with pulmonary arterial hypertension. Circulation 2012; 125:324-34.
DOI
ScienceOn
|
27 |
Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol 2011;108:1177-82.
DOI
ScienceOn
|